Previous 10 | Next 10 |
Summary Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating Field to be approved for non-small cell lung cancer sometime next year. Later this year, two huge Phase 3 studies are set to r...
Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients t...
Shares of NovoCure (NASDAQ: NVCR) , a maker of niche medical devices, shot about 68% higher on Jan. 5. Investors were cheering clinical trial results for what could be the company's most important product to date. Is NovoCure a good stock to buy now, or will its recent gains fizzl...
Novocure (NASDAQ: NVCR) stock rallied hard during Thursday's trading session while most growth stocks were selling off. In the video below, I explain why the stock is flying high. I also share a brief background of Novocure and look at a chart to tell you where the stock could be headed nex...
Shares of Chinese biotech company Zai Lab Limited (NASDAQ: ZLAB) were up more than 59.2% for the week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed at $30.70 on Friday and rose to as high as $49.81 on Thursday. Zai La...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CHIARI VFX / Shutterstock Huadi International (NASDAQ: HUDI ) stock is climbing higher on Thursday even without specific news from the Chinese steel company. What appears to be behind today’s moveme...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/ZinetroN Magic Empire Global (NASDAQ: MEGL ) stock is rocketing higher on Thursday despite a lack of news from the Hong Kong financial services provider. Instead, it looks like speculation...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips What’s driving the NovoCure (NASDAQ: NVCR ) stock price by more than 50% today? The big news concerns NovoCure’s proposed treatment for a particular type of lung cancer. A clinical study has met its primary en...
Shares of Novocure (NASDAQ: NVCR) are skyrocketing 49.8% higher as of 10:12 a.m. ET on Thursday. The huge jump came after the company announced the results from a late-stage clinical study evaluating its Tumor Treating Fields (TTFields) therapy in treating stage 4 non-small cell lung canc...
The stock market remained volatile on Thursday, with investors reacting negatively to signs that the economy might be too strong for the Federal Reserve to slow the pace of its interest rate increases. After having been slightly higher earlier in the morning, the Nasdaq Composite (NASDAQIND...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...